Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Tebentafusp for Uveal Melanoma: Cytokine Release Syndrome

August 2nd 2021

Advice to help educate patients about symptoms and management of cytokine release syndrome following treatment with tebentafusp for uveal melanoma.

Tebentafusp for Uveal Melanoma: Adverse Events

August 2nd 2021

What to know about treatment response and treatment-related adverse events with tebentafusp for uveal melanoma.

Uveal Melanoma: Sequencing Therapy

August 2nd 2021

Potential sequencing strategies with novel therapies such as tebentafusp for uveal melanoma.

FDA Grants Fast Track Status to Nemvaleukin Alfa for Mucosal Melanoma

August 2nd 2021

The FDA has granted a fast track designation to nemvaleukin alfa as a potential therapeutic option for patients with mucosal melanoma.

Tebentafusp for Uveal Melanoma: Assessing Treatment Response

July 23rd 2021

Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression.

Tebentafusp Efficacy Data in Uveal Melanoma

July 23rd 2021

Implications for treating uveal melanoma with tebentafusp based on responses demonstrated by the IMCgp100-102 and IMCgp100-202 clinical studies.

Tebentafusp for Uveal Melanoma

July 23rd 2021

Drs Richard D. Carvajal and Marlana M. Orloff comment on tebentafusp’s mechanism of action (MOA) and explain what makes the therapy attractive for uveal melanoma.

Uveal Melanoma: Current Treatment Approaches

July 23rd 2021

A brief explanation regarding the difference between uveal melanoma and skin melanoma and an overview of standard treatment approaches used to treat patients with uveal melanoma.

FDA Grants Orphan Drug Designation to Alrizomadlin for Stage IIB-IV Melanoma

July 21st 2021

The FDA has granted an orphan drug designation to alrizomadlin as a potential therapeutic option for patients with stage IIB-IV melanoma.

Dr. Thomas on the Safety Profile of Lifileucel Plus Pembrolizumab in Advanced Melanoma

July 19th 2021

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

Frontline Bempegaldesleukin/Nivolumab Continues to Elicit Durable Responses in Metastatic Melanoma

July 14th 2021

The combination of bempegaldesleukin plus nivolumab continued to produce promising antitumor activity with favorable tolerability when used in the frontline treatment of patients with metastatic melanoma, according to findings from a phase 2 cohort of the phase 1/2 PIVOT-2 trial.

Belapectin/Pembrolizumab Shows Early Activity, Tolerability in Metastatic Melanoma & Head and Neck Cancer

July 11th 2021

The combination of belapectin plus pembrolizumab has demonstrated early potential for disease control with acceptable tolerability in patients with metastatic melanoma and head and neck cancer.

FDA Approves Pembrolizumab for Locally Advanced Cutaneous Squamous Cell Carcinoma

July 6th 2021

The FDA has expanded the label for pembrolizumab for use as a monotherapy in the treatment of patients with locally advanced cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

Cemiplimab Approved in Europe for PD-L1+ NSCLC, Basal Cell Carcinoma

June 25th 2021

The European Commission has granted approval to cemiplimab for the treatment of patients with locally advanced or metastatic non–small cell lung cancer whose tumor cells have at least 50% PD-L1 expression and no EGFR, ALK, or ROS1 aberrations and are ineligible for definitive chemoradiation.

Dr. Tawbi on the Safety Profile of Relatlimab Plus Nivolumab in Advanced Melanoma

June 24th 2021

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

Novel Targets Set to Add to Checkpoint Blockade Success in Merkel Cell Carcinoma

June 15th 2021

James A. DeCaprio, MD, discusses the incidence of Merkel cell carcinoma, risk factors for the disease, established treatment options, and investigational regimens on the horizon.

Patel Previews Collaborative Research Program With SD-101 in Uveal Melanoma

June 10th 2021

Dr. Patel discusses the significance of the new collaboration between The University of Texas MD Anderson Cancer Center and TriSalus™ Life Sciences.

Alrizomadlin/Pembrolizumab Induces Early Efficacy in Unresectable Melanoma or Advanced Solid Tumors

June 8th 2021

The addition of alrizomadlin to pembrolizumab yielded promising preliminary efficacy and was tolerable in patients with unresectable or metastatic melanoma or advanced solid tumors that have been resistant to immunotherapy agents.

Lenvatinib/Pembrolizumab Yields Continuing Efficacy in Advanced Melanoma

June 6th 2021

Lenvatinib and pembrolizumab continued to yield meaningful and durable responses in patients with advanced melanoma who had progressed on previous PD-L1 inhibitor treatment.

Lifileucel Continues to Demonstrate Durable Responses in Heavily Pretreated Advanced or Metastatic Melanoma

June 6th 2021

Lifileucel has demonstrated promising long-term responses in patients with heavily pretreated advanced or metastatic melanoma who have progressed following PD-1 and PD-L1 inhibition.